PAVmed to Participate in September Investor and MedTech Conferences
September 07 2021 - 10:04AM
Business Wire
Presentations scheduled at Lake Street Capital
Markets BIG5, Cantor Fitzgerald Virtual Global Healthcare, and The
MedTech Conference
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”
or “PAVmed”), a highly differentiated, multi-product,
commercial-stage medical technology company, today announced the
company’s management team will participate in the Lake Street
Capital Market's Best Ideas Growth (BIG5) Conference, the Cantor
Fitzgerald Virtual Global Healthcare Conference, and The MedTech
Conference.
Presentation Details:
Lake Street Capital Market’s BIG5 Conference Date: September 14,
2021 Time: 8:00 a.m. – 4:05 p.m. EDT Conference Link:
https://bit.ly/2WU9LYf
Cantor Fitzgerald Virtual Global Healthcare Conference Date:
September 30, 2021 Time: 11:20 a.m. EDT Registration Link:
https://bit.ly/3yL7lI8
The MedTech Conference Date: September 30, 2021 Time: 10 a.m.
EDT Event Link for Session, Early Stage Medtech and Going Public:
https://bit.ly/3kVWbLM
About PAVmed
PAVmed Inc. is a highly differentiated, multi-product,
commercial-stage medical technology company with a diversified
product pipeline addressing unmet clinical needs encompassing a
broad spectrum of clinical areas with attractive regulatory
pathways and market opportunities. Major subsidiary, Lucid
Diagnostics Inc., markets the first and only commercial tools for
widespread early detection of esophageal precancer and cancer – the
EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell
Collection Device. The GI Health Division also includes the
complementary EsoCure™ Esophageal Ablation Device with Caldus™
Technology. The Minimally Invasive Interventions Division markets
its CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome.
Another major subsidiary, Veris Health Inc., is a digital health
company developing the first intelligent implantable vascular
access port with biologic sensors and wireless communication to
improve personalized cancer care through remote patient monitoring.
Other divisions include Infusion Therapy (PortIO™ Implantable
Intraosseous Vascular Access Device and NextFlo™ Intravenous
Infusion Set), and Emerging Innovations (non-invasive laser-based
glucose monitoring, pediatric ear tubes, and mechanical circulatory
support). For more information, please visit www.pavmed.com, follow
us on Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of
PAVmed’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, volatility in the price of PAVmed’s
common stock, Series W Warrants and Series Z Warrants; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required
advance PAVmed’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005606/en/
Investors: Lisa DeScenza LaVoieHealthScience (617)
351-0243 ldescenza@lavoiehealthscience.com Media: Katie
Gallagher / Kristi Bruno LaVoieHealthScience (617) 792-3937 / (617)
865-3940 kgallagher@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Apr 2023 to Apr 2024